PA
SLDB icon

Perceptive Advisors’s Solid Biosciences SLDB Stock Holding History

Perceptive Advisors’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-13
Closed -$23K – 120
2019
Q2 		$23K Buy
+13
New +$1.42K ﹤0.01% 104
2019
Q1 		– Sell
-122
Closed -$14K – 117
2018
Q4 		$14K Buy
+122
New +$57.4K ﹤0.01% 101

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Perceptive Advisors's SLDB Position: Q2 2026 in Review

Perceptive Advisors held its Solid Biosciences (SLDB) position steady in Q2 2026 at 11,906,646 shares worth $119M. The position accounts for 1.79% of the portfolio, ranked #18.

Perceptive Advisors first reported a position in SLDB in Q4 2018 and has held it in 28 quarters since. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Perceptive Advisors held 11,906,646 shares of Solid Biosciences worth $119M as of Q2 2026.
  • Perceptive Advisors left its Solid Biosciences share count unchanged in Q2 2026.
  • Solid Biosciences made up 1.79% of Perceptive Advisors's portfolio in Q2 2026, its #18 holding.
  • Perceptive Advisors first reported a position in Solid Biosciences in Q4 2018 and has held it in 28 quarters since.
  • 157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.